Business Wire

NY-UNITED-FIRST-PARTNERS

1.10.2018 13:47:05 CEST | Business Wire | Press release

Share
United First Partners Continues to Increase its Commitment to Research – Hires Another Four Analysts in London and New York

United First Partners (“UFP”), a leading independent Equity Research, Advisory and Brokerage firm, providing event driven and special situations equities research and execution, adds four analysts in London and New York.

UFP has hired Bruno Burki, as a London based research salesperson. Prior to joining UFP, Bruno was head of event driven research at Square Global Markets and previously a senior Associate in the UK M&A team at Barclays in London, where he advised corporates and financial sponsors on a wide range of strategic transactions. Bruno notably advised ENOC in their acquisition of the minorities’ stake they didn't own in Dragon Oil, and International Power in their defence against GDF.

In addition, UFP hired Patryk Basiewicz (CFA) as a special situations analyst. Patryk joined UFP from Olivetree where he was a TMT Sector Strategist. At Olivetree, Patrick was responsible for formulation of investment ideas in European TMT equity space and handled fundamental aspects of Olivetree’s Event-driven product. Previous roles include buyside analyst positions as well as management consultant at McKinsey & Co.

The London unit also hired Josh Rosen as a special situations analyst. Prior to joining UFP, Josh was an Investment Banking Associate at Citigroup in London in the FIG group, where he worked on large-cap M&A deals across the banking and insurance sectors, as well as IPOs and capital markets financing. Prior to this, Josh held roles in Wealth & Investment Management at Citigroup and Barclays in London and Geneva where he advised Ultra High Net Worth clients.

In New York, UFP reinforced its research team with the hiring of Maggie Bishop. She joins UFP from Wells Fargo Securities in Houston where she was an Analyst in the Energy Investment Banking Group, involved in a wide variety of mergers and acquisitions, capital markets financings and strategic advisory assignments for clients across the upstream, midstream, and oilfield services sectors.

United First Partners CEO Stephane Mardel commented: “One of UFP group’s key strength is the delivery of unique, actionable and thorough research work across the globe. With the hiring of Bruno, Patryk, Josh and Maggie, UFP continues to offer one of the largest special situations research platform on the street, with diversified talents, covering multiple industries. These new hires help complement the skills of our existing established research teams in London and New York, demonstrating our commitment to producing top tier special situations research, and our desire to work relentlessly to maximise value for our clients.”

About UFP and Mariana UFP

United First Partners is an independent global financial services firm, with a strong reputation and leading position in the Equities and Derivatives space. UFP’s award winning research reflects UFP’s commitment to excellence in Special Situations Research, providing best in class and in-depth research coverage on companies where specific events may act as a catalyst for material price actions, using fundamental analysis and unique in-house legal resources. United First Partners and Mariana entered into a strategic alliance in May 2017 to generate synergies across the group’s complementary business lines and play an active role in the industry consolidation. Mariana UFP offers comprehensive cross-asset services in Europe & Australia (through Mariana UFP LLP, regulated by the FCA), in North America (through United First Partners LLC, SEC regulated and member of FINRA and SIPC) and in the UAE (through UFP Capital Markets (DIFC) Limited, regulated by the DFSA). The Mariana UFP group also offers structured products, advisory and asset management services.

Contact:

United First Partners Stephane Mardel +442030174330 stephane.mardel@utdfirst.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye